Business Impact Risk from COVID-19
First written in FY2020-Q2. 15 of 19 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2025ReframedAnnual report
「If a serious infectious disease such as novel influenza or COVID-19 spreads, employees may become infected, forcing us to suspend various business activities, including development and sales.」
The description has been reframed from its previous focus on COVID-19 as the risk of business interruption due to serious infectious diseases generally, including novel influenza and other diseases. Measures such as maintaining spacing between seats and partial work-from-home arrangements are continuing. - FY2024RestatedAnnual report
「Although infectious diseases including COVID-19 and influenza have not had a significant impact on development or sales schedules at this time, if infections spread beyond expectations and employees become infected, forcing us to suspend various business activities, including development and sales, our business performance could be affected.」
Continues to describe the risk of suspending business activities due to infectious diseases including COVID-19 and influenza, while stating that there has been no significant impact on development or sales schedules at this time. - FY2024-Q2RestatedAnnual report
「During the cumulative second-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
States that there has been no new occurrence or material change in the risk of business impact from infectious diseases including COVID-19. - FY2024-Q1RestatedAnnual report
「During the six months ended [current first quarter], there was no emergence of new business or other risks, nor any material change in the business or other risks described in the annual securities report for the previous fiscal year.」
States that there has been no new occurrence or material change in the risk of business impact from infectious diseases including COVID-19. - FY2023ReframedAnnual report
「Although infectious diseases including COVID-19 and influenza have not had a significant impact on development or sales schedules at this time, if infections spread beyond expectations and employees become infected, forcing us to suspend various business activities, including development and sales, our business performance could be affected.」
The risk has been reframed from a description centered on COVID-19 to a general infectious-disease risk that includes influenza and other diseases. Measures including expanding office space and introducing partial work-from-home arrangements continue. - FY2023-Q3RestatedAnnual report
「COVID-19 has had no significant impact at this time, but we will continue to monitor developments closely.」
Reconfirms that COVID-19 has had no significant impact at this time and that developments will continue to be monitored closely. - FY2023-Q2RestatedAnnual report
「COVID-19 has had no significant impact at this time, but we will continue to monitor developments closely.」
Reconfirms that COVID-19 has had no significant impact at this time and that developments will continue to be monitored closely. - FY2023-Q1RestatedAnnual report
「COVID-19 has had no significant impact at this time, but we will continue to monitor developments closely.」
Reconfirms that COVID-19 has had no significant impact at this time and that developments will continue to be monitored closely. - FY2022RestatedAnnual report
「Although COVID-19 has not had a significant impact on development or sales schedules at this time, if infections spread beyond expectations and employees become infected, forcing us to suspend various business activities, including development and sales, our business performance could be affected.」
Continues to state that there has been no significant impact on development or sales schedules at this time, while describing the risk of suspending business activities if infections spread and the measures of expanding office space and introducing partial work-from-home arrangements. - FY2022-Q3RestatedAnnual report
「COVID-19 has had no significant impact at this time, but we will continue to monitor developments closely.」
Reconfirms that COVID-19 has had no significant impact at this time and that developments will continue to be monitored closely. - FY2022-Q2RestatedAnnual report
「COVID-19 has had no significant impact at this time, but we will continue to monitor developments closely.」
Reconfirms that COVID-19 has had no significant impact at this time and that developments will continue to be monitored closely. - FY2022-Q1RestatedAnnual report
「COVID-19 has had no significant impact at this time, but we will continue to monitor developments closely.」
Reconfirms that COVID-19 has had no significant impact at this time and that developments will continue to be monitored closely. - FY2021MitigatedAnnual report
「Although COVID-19 has not had a significant impact on development or sales schedules at this time, if infections spread beyond expectations and employees become infected, forcing us to suspend various business activities, including development and sales, our business performance could be affected. In addition to implementing thorough infection-control measures, we are working to minimize the impact of infectious diseases by expanding our office floor space to ensure greater distance between employees’ seats and by combining this with partial work-from-home arrangements.」
Maintains the explanation that there has been no significant impact on development or sales schedules at this time, while describing specific measures, including expanding office space and introducing partial work-from-home arrangements. - FY2021-Q3RestatedAnnual report
「COVID-19 has had no significant impact at this time, but we will continue to monitor developments closely.」
Reconfirms that COVID-19 has had no significant impact at this time and that developments will continue to be monitored closely. - FY2021-Q2RestatedAnnual report
「COVID-19 has had no significant impact at this time, but we will continue to monitor developments closely.」
Continues to state that COVID-19 has had no significant impact at this time and that developments will continue to be monitored closely. - FY2021-Q1RestatedAnnual report
「COVID-19 has had no significant impact at this time, but we will continue to monitor developments closely.」
Continues to state that COVID-19 has had no significant impact at this time and that developments will continue to be monitored closely. - FY2020RestatedAnnual report
「COVID-19 has had no significant impact at this time, but we will continue to monitor developments closely.」
Continues to state that COVID-19 has had no significant impact at this time and that developments will continue to be monitored closely. - FY2020-Q3RestatedAnnual report
「Although no impact on the business from COVID-19 has occurred at this time, we will continue to monitor developments closely, as the situation remains uncertain.」
States that COVID-19 has not affected the business at this time and reconfirms the policy of continuing to monitor developments closely. - FY2020-Q2First statedAnnual report
「Although no impact on the business from COVID-19 has occurred at this time, we will continue to monitor developments closely, as the situation remains uncertain.」
For the first time, describes the risk that the business may be affected by COVID-19, while stating that no impact has occurred at this time and that developments will continue to be monitored closely.